UNSPSC 51172319: Cysteamine or mercaptamine

This classification denotes an anti-ulcer agent with the molecular formula C2H7NS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5UX2SD1KE2, chemically known as 2-mercaptoethylamine, polymer-bound but generally known as cysteamine, which bears US NIH Compound Identifier 6058. European Medicines Agency schedules Cysteamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08770MIG. The term CYSTEAMINE is an International Non-Proprietary Name.

World Health Organization schedules cysteamine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, CYSTEAMINE remains the US FDA Preferred Term for this commodity. Cysteamine bears US NLM identifiers UMLS ID C0010648 and NCI Concept Code C61696. SMILES: C(CS)N.

UNSPSC 51172319 Cysteamine or mercaptamine, a Commodity code, covers pharmaceutical chemical reagents and testing compounds that state and local governments procure primarily for clinical laboratory and correctional healthcare operations. Recent solicitations show this code applies to drug-testing specimen analysis and pharmaceutical supply chains in correctional and public health settings, where state and local agencies source testing reagents, confirmation assays, and pharmaceutical ingredients through formal RFPs and cooperative purchasing agreements.

State and local issuing bodies under this code include county correctional departments, state pharmacy benefit programs, and multistate cooperative purchasing alliances coordinating procurement across participating jurisdictions. Collin County Community Supervision and Corrections Department and the Texas Health and Human Services Commission represent the primary recent buyers. The code shows activity concentrated in Texas and the upper Midwest. Representative recent opportunities include Collin County's RFP 2026-327 for offender specimen collection and drug testing services (due July 23, 2026, estimated contract value $600,000 over two years with optional renewals), which calls for immunoassay screening with LC/MS/MS or GC/MS confirmation testing at two collection sites performing approximately 25,031 annual tests; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (due March 26, 2026), which establishes multiple contracts for statewide and regional distribution through authorized wholesalers with vendor pricing weighted 75 percent in evaluation. Texas Health and Human Services Commission also issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling potential future procurement activity in pharmaceutical supply models outside traditional pharmacy benefit manager arrangements.